Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Recordati Considers €10.9B CVC Capital Acquisition Offer Before Q1 Close
Italian pharma Recordati weighs a €10.9bn acquisition offer from CVC Capital. Discover the details of this major M&A deal ahead of the Q1 2026 close.
Simulations Plus and Pharma Partners Advance AI-Driven Drug Development
Simulations Plus announces strategic partnerships with three pharmaceutical companies to integrate AI into model-informed drug development workflows.
Wave Life Sciences Stock Plummets 50% on Weak Phase I Obesity Trial Data
Wave Life Sciences' stock crashed 50% after its Phase I obesity trial for WVE-007 showed lower-than-expected weight loss, disappointing investors.
FDA Approves Novo Nordisk's Awiqli®: First Once-Weekly Insulin for T2D
The FDA has approved Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults living with type 2 diabetes to improve A1C.
Assessing Ipsen Valuation After New Preclinical Oncology Data at AACR
Ipsen's valuation comes into focus following new preclinical data at AACR for first-in-class oncology candidates IPN01203 and IPN60300 in solid tumors.
CDR-Life's Experimental MS Therapy CDR111 Meets Preclinical Milestone
Experimental MS therapy CDR111, developed by CDR-Life and Boehringer Ingelheim, advances after meeting a key preclinical milestone in B-cell depletion.
Alzheimer’s Disease May Be an Autoimmune Condition, New Theory Suggests
A new theory proposes Alzheimer's is an autoimmune disease of the brain's immune system, challenging the 30-year-old beta-amyloid cascade hypothesis.
FoRx Therapeutics Unveils FORX-428 Preclinical Data at ACS Spring 2026
FoRx Therapeutics presents preclinical data at ACS Spring 2026 for FORX-428, a novel PARG inhibitor targeting treatment-resistant cancers.
FDA Approves Denali's Avlayah Drug for Hunter Syndrome: Rare Disease Win
The FDA approves Denali Therapeutics' Avlayah, the first enzyme replacement therapy addressing cognitive symptoms of Hunter syndrome, a rare genetic disease.
Biolojic Design Reaches Teva Milestone for AI-Designed Multibody TEV ‘325
Biolojic Design earns a preclinical milestone payment from Teva for TEV ‘325, a novel AI-designed multibody targeting autoimmune diseases like asthma.
FDA Grants Sanofi's Venglustat Breakthrough Therapy for Gaucher Type 3
Sanofi's oral medication Venglustat receives FDA Breakthrough Therapy status for Gaucher type 3, showing potential to manage neurological symptoms effectively.
Earendil Labs Lands $787M to Accelerate AI Biologics Development Push
Earendil Labs secures $787m backed by Sanofi to expand its AI-driven drug discovery platform and progress its pipeline of 40+ biologic programs.
1
2
3
4
5
